TY - JOUR
T1 - Safety of tPA in stroke mimics and neuroimaging-negative cerebral ischemia
AU - Chernyshev, O. Y.
AU - Martin-Schild, S.
AU - Albright, K. C.
AU - Barreto, A.
AU - Misra, V.
AU - Acosta, I.
AU - Grotta, J. C.
AU - Savitz, S. I.
N1 - Funding Information:
Dr. Chernyshev, Dr. Martin-Schild, Dr. Albright, Dr. Barreto, Dr. Misra, and Dr. Acosta report no disclosures. Dr. Grotta serves on a scientific advisory board for Lundbeck, Inc.; serves on the editorial board of the International Journal of Stroke; holds US Patents 6,500,834, 6,503,915, and 6,503,916 (issued: 1/7/03): A Composition and Method for Treatment of Cerebral Ischemia and received a license fee payment from InnerCool technology; receives royalties from the publication of Acute Stroke Care: A Manual from the University of Texas–Houston Stroke Team (Cambridge, 2007) and Stroke: Pathophysiology, Diagnosis, and Management (Churchill Livingstone, 2004); has received speaker honoraria for lectures not sponsored by industry; and receives research support from the NIH/NINDS (P50 NS 044227 [PI], R01 NS052971 [Co-I], P01 NS046588-02 [Co-I], and T32-NS0074212-11 [PI]) and from the Burnett Family Stroke Fund, and from the Harold Farb Research Fund. Dr. Savitz serves on a scientific advisory board for Grupo Ferrer Internacional S.A.; has received travel expenses and/or honoraria for lectures or educational activities not funded by industry; serves as an Associate Editor of Experimental and Translational Stroke Medicine; has received honoraria from Johnson & Johnson; and receives research support from Athersys, the NIH R21NS064316 (PI) and R21 HD060978 (PI), the American Heart Association, and the Howard Hughes Medical Institute.
Funding Information:
Study funding: Supported by National Institutes of Health (NIH) training grant T32NS04712 and P50 NS044227 and American Heart Association 0475008N.
PY - 2010/4
Y1 - 2010/4
N2 - Background: Patients with acute neurologic symptoms may have other causes simulating ischemic stroke, called stroke mimics (SM), but they may also have averted strokes that do not appear as infarcts on neuroimaging, which we call neuroimaging-negative cerebral ischemia (NNCI). We determined the safety and outcome of IV thrombolysis within 3 hours of symptom onset in patients with SM and NNCI. Methods: Patients treated with IV tissue plasminogen activator (tPA) within 3 hours of symptom onset were identified from our stroke registry from June 2004 to October 2008. We collected admission NIH Stroke Scale (NIHSS) score, modified Rankin score (mRS), length of stay (LOS), symptomatic intracerebral hemorrhage (sICH), and discharge diagnosis. Results: Among 512 treated patients, 21% were found not to have an infarct on follow-up imaging. In the SM group (14%), average age was 55 years, median admission NIHSS was 7, median discharge NIHSS was 0, median LOS was 3 days, and there were no instances of sICH. The most common etiologies were seizure, complicated migraine, and conversion disorder. In the NNCI group (7%), average age was 61 years, median admission NIHSS was 7, median discharge NIHSS was 0, median LOS was 3 days, and there were no instances of sICH. Nearly all SM (87%) and NNCI (91%) patients were functionally independent on discharge (mRS 0-1). Conclusions: Our data support the safety of administering IV tissue plasminogen activator to patients with suspected acute cerebral ischemia within 3 hours of symptom onset, even when the diagnosis ultimately is found not to be stroke or imaging does not show an infarct.
AB - Background: Patients with acute neurologic symptoms may have other causes simulating ischemic stroke, called stroke mimics (SM), but they may also have averted strokes that do not appear as infarcts on neuroimaging, which we call neuroimaging-negative cerebral ischemia (NNCI). We determined the safety and outcome of IV thrombolysis within 3 hours of symptom onset in patients with SM and NNCI. Methods: Patients treated with IV tissue plasminogen activator (tPA) within 3 hours of symptom onset were identified from our stroke registry from June 2004 to October 2008. We collected admission NIH Stroke Scale (NIHSS) score, modified Rankin score (mRS), length of stay (LOS), symptomatic intracerebral hemorrhage (sICH), and discharge diagnosis. Results: Among 512 treated patients, 21% were found not to have an infarct on follow-up imaging. In the SM group (14%), average age was 55 years, median admission NIHSS was 7, median discharge NIHSS was 0, median LOS was 3 days, and there were no instances of sICH. The most common etiologies were seizure, complicated migraine, and conversion disorder. In the NNCI group (7%), average age was 61 years, median admission NIHSS was 7, median discharge NIHSS was 0, median LOS was 3 days, and there were no instances of sICH. Nearly all SM (87%) and NNCI (91%) patients were functionally independent on discharge (mRS 0-1). Conclusions: Our data support the safety of administering IV tissue plasminogen activator to patients with suspected acute cerebral ischemia within 3 hours of symptom onset, even when the diagnosis ultimately is found not to be stroke or imaging does not show an infarct.
UR - http://www.scopus.com/inward/record.url?scp=77951731600&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77951731600&partnerID=8YFLogxK
U2 - 10.1212/WNL.0b013e3181dad5a6
DO - 10.1212/WNL.0b013e3181dad5a6
M3 - Article
C2 - 20335564
AN - SCOPUS:77951731600
SN - 0028-3878
VL - 74
SP - 1340
EP - 1345
JO - Neurology
JF - Neurology
IS - 17
ER -